Five months after Sanofi backed away from a proposed deal with Maze Therapeutics on a Pompe disease therapy after an antitrust challenge, Shionogi has snapped up the drug.
Digital health company Akili is on the brink of its first major expansion beyond the US, partnering with Shionogi to file a localised version of its attention deficit hype
F2G’s attempt to end a two-decade drought in novel therapies for invasive fungal infections has hit a hurdle after the FDA said it was unable to approve its olorofim candi
A Japanese language version of Akili Interactive's EndeavorRx ground-breaking digital therapy for attention deficit hyperactivity disorder (ADHD) has started a phase 3 trial, with results d
Join the conversation, on Tuesday 28th January @ 10 am ET - 3 pm GMT - 4 pm CET, in our webinar sponsored by Syneos Health, entitled ‘Health Trends 2025: Reimagining What's Possibl
